Pioneering technology for protein production
During our last financial year progress against our strategic objectives included:
Gene editing
- Conducted further trials on our gene-edited pigs, demonstrating complete resistance to two prevalent types of PRRSv, and made our second submission for regulatory approval in the US
- With our partner BCA, increased interactions with MARA and progressed in-country lab and production facilities
- Continued our collaboration with Kansas State University to evaluate opportunities for combating swine influenza and African Swine Fever
Gender skew
- Introduced a second generation of our industry-leading sexing technology to enhance ease of operation, improve efficiency and increase the gender skew rate of each unit produced
- Increased production capacity to help ABS meet global demand for its sexed semen product, Sexcel
- Continued to expand our network of IntelliGen Technologies laboratories, which now number 11 owned and licensed facilities across four continents
Reproductive biology
- Harnessed new techniques and technologies to improve our system for IVF, enhancing the quality and quantity of embryos produced internally and within licensed laboratories
- Started exploring the benefits of working with embryonic stem cells to accelerate genetic gain, through collaborations with the University of California Davis and Missouri State University
Data strategy
- Developed a data and analytics strategy and implemented initiatives on scalable hybrid computing, flexible storage and cataloguing of assets to strengthen data science capabilities and support innovation